

Immutep AGM 2024 Presentation

22 November 2024 (ASX: IMM; NASDAQ: IMMP)

Unlocking the power of the immune system to fight cancer and autoimmune disease



The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This presentation is authorised for release by the CEO of Immutep Limited.



Agenda

Overview of Immutep

Highlights & Outlook

→ Efti Program & Strategy

→ IMP761 Program

→ Summary



Overview of Immutep



Pure-play LAG-3 company with deep pipeline in oncology & autoimmune diseases:	 Multiple LAG-3 Programs – Four clinical-stage assets and one preclinical program Upcoming Milestones – Multiple data updates from clinical programs 	
Lead candidate Efti addressing therapeutic gaps across the solid tumor treatment landscape:	 First-in-class MOA – As unique MHC Class II agonist, efti activates innate and adaptive anti-tumor immunity Activity across PD-L1 spectrum – Activity in hot/tepid/cold tumors addressing high unmet needs Consistent Outcomes – Improved survival across multiple indications with mature data Favourable Safety – Well-tolerated profile with standard-of-care IO and/or chemotherapy Manufacturing – Achieved 2000L commercial scale production; authorization for clinical trial use granted in Sept '23 	Efti-Chemo Combination
Strong IP/Balance Sheet:	 Intellectual Property – Comprehensive IP portfolio; innovative biologics also potentially entitled to test data exclusivity (e.g., up to 12 years in US) Well-Financed – Cash, cash equivalent and term deposit position totalling ~A\$172.3 million¹ providing expected runway to end of 2026 	

Deep LAG-3 Pipeline in Oncology & Autoimmune Diseases







Information current as of September 2024. For EOC's China rights, Immutep may receive undisclosed milestones plus royalties; LAG525 (ieramilimab)- ClinicalTrials.gov (for Novartis' global rights, Immutep may receive milestones plus royalties); Immutep has no control over the trials. § Investigator Initiated Trials controlled by lead investigator & therefore Immutep has no control over these clinical trials. § Investigator Initiated Trials controlled by lead investigator & therefore Immutep has no control over these clinical trials. In combination with KEYTRUDA[®]. In combination with BAVENCIO[®]. # Late stage refers to active Phase IIb clinical trials or more clinically advanced clinical trials. # Conducted by EOC in China.* IMP731 - The clinical-stage asset GSK'781 is being transitioned back to Immutep as the licensing agreement has been terminated with an effective date of 30 May 2024. ** IMP761 – Phase I study to launch mid-CY2024.

Pioneering LAG-3 Immunotherapy Portfolio





Immutep has designed multiple first-in-class therapeutics targeting either **MHC Class II molecules** on antigen-presenting cells (APC) or **LAG-3** on T-cells to fight cancer & autoimmune disease



MHC Class II = Major Histocompatibility Complex Class II. * LAG525 (leramilimab) is out-licensed to Novartis. The clinical-stage asset GSK'781 (IMP731) is being transitioned back to Immutep as the licensing agreement has been terminated with an effective date of 30 May 2024.



Highlights & Outlook

2024 Clinical Milestones



Non-small cell lung cancer



TACTI-004

Phase III TACTI-004 trial (KEYNOTE-PNC-91) tests efti in combination with KEYTRUDA® and chemotherapy in ~750 first-line metastatic NSCLC patients regardless of PD-L1 expression

- Advanced preparations for the trial, including productive interactions with regulatory agencies and other stakeholders
- Signed third clinical trial collaboration with MSD, receiving its key drug KEYTRUDA at no cost, while retaining commercial rights to efti
- Study start in late CY2024 or Q1 CY2025

INSIGHT-003

- Very encouraging mOS data (32.8 m) released from first 21 patients
- 55% ORR from 40 patients
- Recruitment ongoing

Head and neck squamous cell carcinoma

TACTI-003

Phase IIb TACTI-003 trial evaluating efti in combination with KEYTRUDA® in first-line recurrent/metastatic HNSCC, with 171 patients enrolled across 30 countries

- Achieved a 34.5% ORR across all patients, with PD-L1 and strong DOR and DCR, and a 35.5% ORR in PD-L1-negative patientsoutperforming anti-PD-1 monotherapy
- Data presented at ESMO Virtual Plenary session and ESMO annual conference
- FDA Fast Track designation in 1L HNSCC

Metastatic breast cancer

AIPAC-003

AIPAC-003 is an integrated Phase II/III trial evaluating efti in combination with chemotherapy (paclitaxel) for metastatic HER2-neg/low breast cancer and triplenegative breast cancer, which account for ~78% of breast cancer cases

- Encouraging efficacy, safety, and pharmacodynamic data reported from the six patients in the safety lead-in phase
- Patient recruitment finished in the randomised Phase II part
- Data collection and cleaning ongoing with the main task to identify the OBD

Soft tissue sarcoma

EFTISARC-NEO

Phase II, open-label trial, examining the combination of efti, radiotherapy and **KEYTRUDA** in up to 40 patients with soft tissue sarcoma (STS) in the neoadjuvant setting (before surgery)

- Initial efficacy data very encouraging and presented at a conference (first 21 patients)
- Recruitment ongoing

Autoimmune disease

IMP761

First-in-human Phase I clinical trial of IMP761 in healthy volunteers


- Toxicology trial completed
- Dosed first patient, recruitment ongoing

TACTI-004 Trial: Immutep & MSD Phase III Trial in NSCLC

Opportunity to set a new standard of care across entire NSCLC population regardless of PD-L1 expression



TACTI-004 / KEYNOTE-PNC-91 Trial Design



Trial Overview:


- TACTI-004 will be a 1:1 randomized, double-blind, multinational, controlled clinical study with ~750 patients
- Trial will enroll first line squamous and non-squamous NSCLC patients who are unselected for PD-L1 expression
- Dual primary endpoints will be Progression-Free and Overall Survival with both being adequately powered

Key Milestones:

- Study start expected in Q4 2024 / Q1 2025
- Futility analysis expected in late 2025 / early 2026 and interim analysis in late 2026 till mid-2027 (event driven)

INSIGHT-003: Excellent Mature Survival Data

Promising efficacy & safety from first-in-human study evaluating Efti + KEYTRUDA + doublet chemo



Investigator-initiated Phase I study in first line metastatic non-squamous NSCLC regardless of PD-L1 (TPS 0-100)

LAG-3 IMMUNOTH

 Multi-centre trial led by the Frankfurt Institute of Clinical Cancer Research (IKF)

Overall Survival

TPS 0-100

22.0

32.9

• Completion of patient enrollment expected in Q1'2025

35

30

25

20

15

10

5

0




Soft Tissue Sarcoma: Orphan Disease with High Unmet Need


Investigator-initiated trial studying novel triple combination of Efti + Radiotherapy + KEYTRUDA



EFTISARC-NEO Phase II Trial Design^{*}



Rationale for triple combination based on cancer-immune cycle*



12

- First trial studying efti in neoadjuvant setting and with radiotherapy
- Importantly, study will provide access to tumor tissue prior to and after treatment, so tumor microenvironment can be assessed^{**}
- Cost-efficient Phase II study funded by grant from Polish government
- Completion of patient enrollment expected in Q1'2025

Positive data from EFTISARC-NEO presented at CTOS 2024:

- Based on preliminary analysis among 21 patients available for primary endpoint assessment, triple combination with efti demonstrates significant efficacy
- Median 50% tumour hyalinization (primary endpoint and important predictor of overall survival) is greater than 3-fold increase versus historical median 15% from radiotherapy alone
- ✓ 71.4% of patients achieved pathologic response defined as ≥35% of hyalinization/fibrosis
- ✓ 9.5% of patients achieved a complete pathologic response
- ✓ Therapy well tolerated



Manufacturing at Commercial Scale

- Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved
- Regulatory authorisation for efti manufactured at commercial
 2,000L scale
- Enables use in clinical trials across multiple European countries and the United States
- Follows successful scale up of the manufacturing process from the 200L process to 2,000L at WuXi Biologics



Robust Intellectual Property Protection

Efti

- Eight new patents granted in FY24:
 - Protects combinations with chemotherapy or anti-PD-1 therapy in Europe, Korea and Brazil
 - Patent for Immutep's binding assay for determining MHC Class II binding activity in Brazil, Canada, India, Macao, and Russia
- Broad protection for efti across a total of 9 patent families
 IMP761
- Two new patents granted in FY24 in Australia and Mexico



14

Strong cash position of approx. A\$172.3 million including investment in term deposit as of 30 Sept 2024 following A\$100.2 million equity raise in June 2024

Disciplined cash management strategy with focus on the development strategy for efti and IMP761

Total revenue and other income were A\$7.8 million in FY24 compared to A\$5.2 million in FY23

Research and development and intellectual property expenses increased to A\$41.5 million in FY24 due to clinical trial activity and associated expenses

Increases in clinical trial costs drove the increase in R&D expenses and the net loss

Strong cash runway expected to end of CY2026*

	FY24	FY23
Revenue and other income	A\$7.8M	A\$5.2M
G&A Expenses	A\$8.9M	A\$8.7M
R&D and IP expenses	A\$41.5M	A\$36.3M
Net loss	A\$42.7M	A\$39.9M
Net operating cash outflow	A\$34.8M	A\$35.4M
Cash and cash equivalents at the end of the financial year	A\$181.8 M	A\$123.4M
Cash and cash equivalents at 30 September	A\$172.3M	A\$110.1M



2024

• Non-Small Cell Lung Cancer – TACTI-004 preparations for study start in late 2024 / early 2025

Head and Neck Squamous Cell Carcinoma – Update from Cohort B of TACTI-003 trial at the ESMO Immuno-Oncology Congress

Autoimmune Diseases – Safety data from IMP761 first-in-human Phase I trial anticipated by year-end

2025

•

Non-Small Cell Lung Cancer – Potential futility analysis in TACTI-004 Phase III trial by year end 2025; update from INSIGHT-003 trial
 Metastatic Breast Cancer – Update from AIPAC-003 trial

Head and Neck Squamous Cell Carcinoma – Update from TACTI-003 trial

Soft Tissue Sarcoma – Update from investigator-initiated EFTISARC-NEO trial

- Metastatic Urothelial Carcinoma Update from investigator-initiated INSIGHT-005 trial
- Autoimmune Diseases Update from IMP761 first-in-human Phase I trial

Additional Updates – From ongoing clinical trials, partnered programs, and potential expansion of clinical trial pipeline

Well-Funded – Cash, cash equivalent and term deposit totalling ~A\$172.3 million (~US\$119.1 million)¹; runway expected to end of CY2026

personal use only



Thank You